Physician

Alejandra Maria Mena Gutierrez, M.D.

According to 2025 Medicare claims, Alejandra Gutierrez, M.D. (NPI: 1538324215) practices nephrology in the Winston-Salem, NC market, with the plurality of this provider's patient population coming from Forsyth, NC. This provider's primary affiliated billing organization is WAKE FOREST UNIVERSITY HEALTH SCIENCES (NPI: 1003803032; TIN: 223849199) and primary practice location at 27157-0001. Gutierrez is affiliated with the Advocate Physician Partners Accountable Care, Inc. (ACO ID: A1033), participating under the MSSP model.

Gutierrez's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 106 traditional Medicare patients, billed 319 HCPCS/CPT codes, and received $24,084 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,708 prescription claims across 174 beneficiaries totaling $532,482 in drug costs, led by Livtencity (Maribavir). DME data shows 1,518 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $12,661 to $532,482. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $659 and ending at $4,555.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	30	72	$13,514
2018	160	301	$18,818
2019	315	815	$44,216
2020	261	761	$41,718
2021	223	580	$46,874
2022	193	522	$40,580
2023	114	303	$25,099
2024	106	319	$24,084

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	21	111	$12,661
2016	N/R	N/R	N/R
2017	14	57	$59,522
2018	101	305	$72,055
2019	252	2,766	$334,916
2020	268	3,191	$541,380
2021	232	2,352	$381,486
2022	198	2,208	$355,324
2023	201	2,256	$336,473
2024	174	1,708	$532,482

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	180	356	$19,136
2019	811	4,633	$370,254
2020	814	4,555	$416,068
2021	638	3,505	$416,055
2022	494	2,598	$236,662
2023	449	2,214	$130,170
2024	281	1,518	$77,855

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	39	120	$102
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	53	85	$68
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	33	77	$57
90935	Hemodialysis procedure with physician evaluation	16	18	$52

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Livtencity	Maribavir	11	308	$277,064
Prevymis	Letermovir	11	308	$80,421
Lokelma	Sodium Zirconium Cyclosilicate	46	1,399	$36,622
Ozempic	Semaglutide	30	1,036	$31,743
Veltassa	Patiromer Calcium Sorbitex	15	510	$18,524

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	62	$42,984
J7518	Mycophenolic acid, oral, 180 mg	N	42	193	$10,198
J7507	Tacrolimus, immediate release, oral, 1 mg	N	63	307	$9,312
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	77	459	$5,793
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	68	281	$4,924

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Alejandra Maria Mena Gutierrez, M.D.?

Tedicare shows public-source Medicare data for Alejandra Maria Mena Gutierrez, M.D. (NPI 1538324215), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alejandra Maria Mena Gutierrez, M.D. have ACO affiliation data?

Alejandra Maria Mena Gutierrez, M.D. is shown with ACO affiliation data for Advocate Physician Partners Accountable Care, Inc. (MSSP, ACO ID A1033).

What billing organization is linked to Alejandra Maria Mena Gutierrez, M.D.?

Alejandra Maria Mena Gutierrez, M.D. is linked to WAKE FOREST UNIVERSITY HEALTH SCIENCES (billing NPI 1003803032) in the available physician profile data.

Does Alejandra Maria Mena Gutierrez, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.